ProShares Ultra Nasdaq Biotechnology (BIB)

NASDAQ: BIB · Real-Time Price · USD
80.27
-4.50 (-5.31%)
At close: May 15, 2026, 4:00 PM EDT
80.36
+0.09 (0.11%)
After-hours: May 15, 2026, 4:15 PM EDT
Assets$77.22M
Expense Ratio0.95%
PE Ration/a
Shares Outn/a
Dividend (ttm)$0.49
Dividend Yield0.61%
Ex-Dividend DateMar 25, 2026
Payout FrequencyQuarterly
Payout Ration/a
Volume7,487
Open82.61
Previous Close84.77
Day's Range80.00 - 82.61
52-Week Low39.75
52-Week High90.91
Betan/a
Holdings263
Inception DateApr 8, 2010

About BIB

Fund Home Page

The ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.

Asset Class Equity
Category Trading--Leveraged Equity
Stock Exchange NASDAQ
Ticker Symbol BIB
ETF Provider ProShares
Index Tracked NASDAQ / Biotechnology

Top 10 Holdings

153.65% of assets
NameSymbolWeight
NASDAQ BIO INDEX SWAP BNP PARIBASn/a37.44%
NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAn/a27.33%
NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAn/a26.16%
NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONALn/a20.47%
NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEn/a19.49%
NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGn/a4.91%
Vertex Pharmaceuticals IncorporatedVRTX4.80%
Gilead Sciences, Inc.GILD4.69%
Amgen Inc.AMGN4.55%
Regeneron Pharmaceuticals, Inc.REGN3.81%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Mar 25, 2026$0.00714Mar 31, 2026
Dec 24, 2025$0.13464Dec 31, 2025
Sep 24, 2025$0.18054Sep 30, 2025
Jun 25, 2025$0.17058Jul 1, 2025
Mar 26, 2025$0.13094Apr 1, 2025
Dec 23, 2024$0.39644Dec 31, 2024
Full Dividend History

Performance

BIB had a total return of 103.21% in the past year, including dividends. Since the fund's inception, the average annual return has been 16.18%.

News

Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

Biotech ETFs are regaining attention as analyst targets signal renewed upside heading into 2026, particularly among small- and mid-cap drug developers. The ProShares Ultra Nasdaq Biotechnology ETF ($B...

3 months ago - TipRanks